Poland - Has the economic crisis affected the Polish pharmaceutical market?

Changes have been made to the reimbursement list due to the economic crisis but the pharmaceutical market will continue to grow.

Whilst many countries have entered recession as a result of the economic crises, Poland’s economy did not shrink in 2009. In fact, it was the only economy in the EU that avoided contraction. Consequently, the impact on the Polish pharmaceutical market will be far less than in other countries of similar development in Central & Eastern Europe, such as Hungary. There will be less of a need to reduce spending on healthcare and the disposable income available for purchasing pharmaceuticals should remain steady, although unemployment is predicted to rise marginally in 2010, which may be detrimental to retail sales.

However, recent changes to the drug reimbursement list do reflect the government’s cost-containment policy that was prompted by the economic downturn. Only two new innovative drugs have been placed on the list, although innovative drugs that had previously been approved for reimbursement were not removed. Over 100 generic drugs were added to the lists, but around 50 were removed. Along with the many medicine price decreases that the MoH has negotiated with several pharmaceutical companies, overall savings are expected to reach 45 million zlotys (US$15.2 million).

Further reading - A detailed analysis of the Polish pharmaceutical market is available from Espicom: The Pharmaceutical Market: Poland (published May 2010)

Poland - To what extent will the economic crisis affect the Polish pharmaceutical market?

The effects of the crisis are expected to be minimal given the country’s economic structure.

Whilst many countries have entered recession as a result of the economic crises, Poland’s economy did not shrink in 2009. In fact, it was the only economy in the EU that avoided contraction. There are a number of reasons for this: Polish businesses tend to rely on their own resources rather than loans and have therefore been less affected by the constraints on lending since the crisis broke out; exports account for only 30% of GDP, compared with 66% in the Czech Republic and 69% in Hungary; and consumer spending has remained high.

Consequently, the impact on the Polish pharmaceutical market will be far less than in other countries of similar development in Central & Eastern Europe, such as Hungary. There will be less of a need to reduce spending on healthcare and the disposable income available for purchasing pharmaceuticals should remain steady, although unemployment is predicted to rise marginally in 2010, which may be detrimental to retail sales. The market will continue to be driven by high import growth and the increased demands on healthcare that are associated with the ageing population.

Further reading - A detailed review of the Polish pharmaceutical market is available from Espicom: The Pharmaceutical Market: Poland (published January 2010)

Ireland - Teva to Cut 315 Jobs in Waterford

Teva is cutting 315 jobs at its plant in Waterford, Ireland, it was announced in September 2009.

The plant, which currently has 730 employees, manufactures tablets and inhalers, but following the job losses the production of tablets will be relocated to a factory in Hungary. It is expected that tablet production at the site will cease within 12 months.

Further reading - An in-depth analysis of the Irish pharmaceutical market is available from Espicom: The Pharmaceutical Market: Ireland (published June 2009)

Hungary - N-Gene Hungary and Mecsek Pharma Receive HUF 1 billion in Funding

N-Gene Hungary and Mecsek Pharma have been approved for HUF 1 billion (US$4.7 million) funding from the Economic Development Program budget, it was announced in August 2009.

N-Gene, a biotech firm, and Mecsek Pharma, an R&D business, are about to start clinical trials of a new diabetes drug, a formula which is the sole intellectual property of N-Gene.

Further reading - A detailed analysis of the Hungarian pharmaceutical market is available from Espicom: The Pharmaceutical Market: Hungary (published June 2009)